The World Health Organisation (WHO) has recommended mifepristone as an additional emergency contraceptive option for preventing pregnancy following unprotected sexual intercourse.
The recommendation specifies that the medicine should be administered as soon as possible and within a five-day window after the sexual encounter. This expansion of available tools is part of the WHO’s new Guidelines on Expanding Contraceptive Options, which were released on Wednesday.
The inclusion of mifepristone provides a broader window of efficacy compared to many existing emergency contraceptive methods. While many current options are most effective when taken within 72 hours, the WHO’s guidance for mifepristone extends this period to 120 hours, offering a different clinical pathway for pregnancy prevention.
Implications for reproductive health services
The decision to include mifepristone in the expanded contraceptive guidelines aims to address gaps in reproductive healthcare access. By providing a recommendation that allows for a five-day window, the WHO is offering more flexibility for individuals who may not have immediate access to traditional emergency contraceptive pills within the first three days.
In many African nations, including Nigeria, the availability and regulation of contraceptive methods are central to public health strategies. The recommendation could influence how national health agencies and pharmaceutical regulators approach the procurement, distribution, and clinical administration of emergency medicines. Health providers will need to distinguish between the use of mifepristone as an emergency contraceptive and its use in medical termination of pregnancy, as the two applications involve different clinical protocols.
Clinical experts note that the effectiveness of any emergency contraceptive remains highest when taken immediately after the event. However, the expanded five-day window provides a critical safety net for those in regions where pharmacy access or medical consultations may be delayed.
The implementation of these guidelines will now depend on how individual countries’ health ministries and regulatory bodies, such as NAFDAC in Nigeria, choose to integrate the recommendation into their national drug registries and clinical practice manuals.
Explore more News stories from Business Elites Africa.
